Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

ORLANDO, FL USA (UroToday.com) - The NCIC/SWOG/UKCCR PR7 study randomized patients with biochemical failure after radiation or surgery plus radiation and no metastases between continuous life long androgen deprivation and intermittent androgen deprivation. The trial showed no difference in overall survival or prostate cancer mortality between continuous and intermittent ADT. The authors hypothesized that in patients on continuous androgen deprivation, higher testosterone values correlate with a reduced time to development of castrate resistant PC and lower CSS. Using 626 patients in the continuous ADT arm of the PR7 trial, the relationship between testosterone and the time to androgen independent progression (PSA > 4 with testosterone < 3nm/L) was examined.

auaAmong the 3 groups (median testosterone < 20, 20-50, and ≥ 50 ng/dl), there was a significant difference in time to hormone resistance: CRPC being not reached, 6.4 years, and 4.2 years for the 3 groups respectively. Patients with testosterone > 20ng/dL were at significantly increased risk of developing hormone resistance (HR 1.9 for T ≥ 50 ng/dL). In men with a higher median testosterone level, there was a shorter time from hormone resistance to PC death.

Dr. Klotz concluded that low nadir serum testosterone on ADT (< 0.7mMol/L or < 20ng/dL) correlates with improved duration of response to ADT in men on continuous androgen deprivation for BCR. Testosterone should be checked regularly in such patients and ADT modified to ensure levels < 0.7mMol/L or < 20ng/dL.

Presented by Laurence Klotz MD, FRCS(C) at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Sunnybrook Health Sciences Centre, Toronto, ON Canada

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

.

 

Calendar
Upcoming urology industry events
August 1-5, 2018 / Sheraton Philadelphia Society Hill Hotel
SUFU Research Foundation Resident Preceptorship 2018
August 3-4, 2018 / Hyatt Regency Washington on Capitol Hill
Best of ASCO 2018 - Washington, DC
August 10-11, 2018 / The Palmer House Hilton, Chicago, IL
Best of ASCO 2018 - Chicago, IL
August 28-31, 2018 / ICS 2018
International Continence Society 2018
Journals
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor